DiCE Clinical Trials Database
Patients undergoing treatment often ask about the possibility of enrolling in a clinical trial. A clinical trial is a scientific study. It tests new molecules in the hope that they are safe and more effective than current treatments.
This database is based on clinicaltrials.gov – a global clinical trials database of all diseases and all molecules in development worldwide. It is a shortened version of this, focusing on current clinical trials related to digestive cancers in Europe. The information is updated daily.
Important to remember: please always discuss with your treating physicians first your considerations of partaking in a clinical trial. They are the best judges of its benefits to your particular case.
| NCT ID | Name | Study type | Phase | Status | Country | Disease type | More infos |
|---|---|---|---|---|---|---|---|
| NCT00002692 | Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00002692 | Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Cancer | Infos |
| NCT00002793 | Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00002793 | Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Metastatic Cancer | Infos |
| NCT00002884 | Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus | Interventional | Phase 3 | Unknown status | France | Esophageal Cancer | Infos |
| NCT00002893 | Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00002896 | Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00003063 | Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer | Interventional | Phase 3 | Unknown status | Greece | Colorectal Cancer | Infos |
| NCT00003063 | Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00003260 | Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00003617 | Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach | Interventional | Phase 3 | Unknown status | Poland | Gastric Cancer | Infos |
| NCT00003617 | Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach | Interventional | Phase 3 | Unknown status | Switzerland | Gastric Cancer | Infos |
| NCT00003617 | Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach | Interventional | Phase 3 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT00004115 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy | Interventional | Phase 3 | Unknown status | United Kingdom | Ovarian Cancer | Infos |
| NCT00004115 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy | Interventional | Phase 3 | Unknown status | United Kingdom | Primary Peritoneal Cavity Cancer | Infos |
| NCT00004236 | Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00004236 | Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT00006112 | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer | Interventional | Phase 2 | Unknown status | France | Carcinoma of the Appendix | Infos |
| NCT00006112 | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006112 | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer | Interventional | Phase 2 | Unknown status | France | Primary Peritoneal Cavity Cancer | Infos |
| NCT00006115 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006117 | Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Belgium | Pancreatic Cancer | Infos |
| NCT00006117 | Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00006468 | Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Austria | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Belgium | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Netherlands | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Norway | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Portugal | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Portugal | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Sweden | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Cancer | Infos |
| NCT00007826 | Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00008047 | Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus | Interventional | Phase 1/Phase 2 | Unknown status | France | Esophageal Cancer | Infos |
| NCT00010062 | Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00010062 | Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Luxembourg | Pancreatic Cancer | Infos |
| NCT00010088 | Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00010088 | Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct | Interventional | Phase 2 | Unknown status | Luxembourg | Pancreatic Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Esophageal Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Gastric Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT00033319 | Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00041262 | Combination Chemotherapy in Treating Patients With Esophageal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Germany | Fallopian Tube Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Germany | Ovarian Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Germany | Primary Peritoneal Cavity Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Hungary | Fallopian Tube Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Hungary | Ovarian Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Hungary | Primary Peritoneal Cavity Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Fallopian Tube Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Ovarian Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Primary Peritoneal Cavity Cancer | Infos |
| NCT00046995 | Combination Chemotherapy in Treating Patients With Colon Cancer | Interventional | Phase 3 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT00070005 | J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma | Interventional | Phase 3 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT00072553 | Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00075452 | Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma | Interventional | Phase 3 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00075465 | Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach | Interventional | Phase 2 | Unknown status | France | Gastric Cancer | Infos |
| NCT00075556 | Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00075595 | Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00075738 | Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer | Interventional | Phase 2 | Unknown status | France | Esophageal Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | France | Liver Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | Ireland | Liver Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | Netherlands | Liver Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00079027 | Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | Interventional | Phase 3 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Portugal | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Colon Cancer | Infos |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00114829 | Preoperative Assessment of Colon Tumor | Interventional | Phase 4 | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT00119912 | NORCCAP: Norwegian Colorectal Cancer Prevention Trial | Interventional | Not Applicable | Active but recruitment closed | Norway | Adenoma | Infos |
| NCT00119912 | NORCCAP: Norwegian Colorectal Cancer Prevention Trial | Interventional | Not Applicable | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT00121914 | Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone | Interventional | Phase 3 | Unknown status | Austria | Carcinoma, Hepatocellular | Infos |
| NCT00134758 | Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients | Interventional | Phase 2/Phase 3 | Unknown status | France | Adenomatous Polyposis Coli, Familial | Infos |
| NCT00141466 | Implementation of a New Strategy to Identify HNPCC Patients | Interventional | Not Applicable | Unknown status | Netherlands | Hereditary Nonpolyposis Colorectal Cancer | Infos |
| NCT00162669 | Bevacizumab in Advanced Hepatocellular Carcinoma | Interventional | Phase 2 | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT00182715 | Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | Ireland | Colorectal Cancer | Infos |
| NCT00182715 | Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00188110 | Performance of the Water-Enema Computed Tomography (WE-CT) | Interventional | Not Applicable | Unknown status | France | Colon Cancer | Infos |
| NCT00189683 | Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00215722 | XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Portugal | Colorectal Carcinoma | Infos |
| NCT00220077 | Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT00220246 | Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer | Observational | N/A | Unknown status | Netherlands | Colorectal Neoplasms | Infos |
| NCT00225641 | Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer | Interventional | Not Applicable | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT00250328 | Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy | Interventional | Phase 1 | Unknown status | Israel | Colon Cancer | Infos |
| NCT00253812 | Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy | Interventional | Not Applicable | Unknown status | United Kingdom | Familial Adenomatous Polyposis | Infos |
| NCT00259532 | Three New Methods for Diagnosing Pancreas Cancer | Interventional | Not Applicable | Unknown status | Denmark | Pancreas Cancer | Infos |
| NCT00268411 | Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 3 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00274872 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Interventional | Phase 2/Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00274885 | Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | Interventional | Phase 4 | Unknown status | France | Cancer | Infos |
| NCT00275119 | Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00276705 | Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | Interventional | Phase 2 | Unknown status | Ireland | Liver Cancer | Infos |
| NCT00276705 | Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | Interventional | Phase 2 | Unknown status | Ireland | Liver Cancer | Infos |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | Interventional | Phase 2 | Unknown status | Netherlands | Liver Cancer | Infos |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | Interventional | Phase 2 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00299299 | Modelling Internal Hepatic Movement With an External Abdominal Marker | Observational | N/A | Unknown status | United Kingdom | Patients With Liver Metastases From Colorectal Cancer | Infos |
| NCT00303745 | Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | Interventional | Phase 2 | Unknown status | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | Interventional | Phase 2 | Unknown status | United Kingdom | Ovarian Cancer | Infos |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | Interventional | Phase 2 | Unknown status | United Kingdom | Primary Peritoneal Cavity Cancer | Infos |
| NCT00319007 | Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis | Interventional | Phase 2 | Unknown status | Netherlands | Adenomatous Polyposis Coli | Infos |
| NCT00346281 | 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT00356161 | HAI Via Interventionally Implanted Port Catheter Systems | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00356161 | HAI Via Interventionally Implanted Port Catheter Systems | Interventional | Phase 2 | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT00357682 | A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia | Interventional | Phase 3 | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00383695 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | Interventional | Phase 2 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT00383695 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | Interventional | Phase 2 | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT00383695 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00392470 | Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer | Interventional | Phase 1 | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT00407186 | Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT00411112 | Sentinel Node in Colon Cancer | Interventional | Not Applicable | Unknown status | France | Colon Cancer | Infos |
| NCT00420394 | Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer | Interventional | Phase 2 | Unknown status | Israel | Stomach Neoplasms | Infos |
| NCT00425425 | Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Esophageal Cancer | Infos |
| NCT00433927 | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00433927 | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | Interventional | Phase 3 | Unknown status | Germany | Neoplasm Metastasis | Infos |
| NCT00435097 | Computer Assisted Early Detection of Liver Metastases From fMRI Maps | Observational | N/A | Unknown status | Israel | Metastatic Colorectal Cancer | Infos |
| NCT00438737 | Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00438737 | Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Metastatic Cancer | Infos |
| NCT00440167 | Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine | Interventional | Phase 3 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00442637 | Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | Interventional | Phase 3 | Unknown status | Netherlands | Colorectal Cancer Metastatic | Infos |
| NCT00450203 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Oesophagogastric Cancer | Infos |
| NCT00450788 | Esophageal Cancer in Northeastern Iran | Observational | N/A | Active but recruitment closed | France | Esophageal Cancer | Infos |
| NCT00450788 | Esophageal Cancer in Northeastern Iran | Observational | N/A | Active but recruitment closed | France | GI Disease | Infos |
| NCT00468416 | Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection | Interventional | Phase 2 | Unknown status | Israel | Colorectal Cancer | Infos |
| NCT00474734 | Intravascular Ultrasound for Hepatocellular Carcinoma Staging | Observational | N/A | Unknown status | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT00478946 | A Study of Picoplatin in Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Russian Federation | Colorectal Cancer | Infos |
| NCT00482222 | Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00482222 | Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Cancer | Infos |
| NCT00486460 | Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer | Interventional | Phase 3 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT00509561 | Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00513266 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | Interventional | Phase 2 | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT00513266 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | Interventional | Phase 2 | Unknown status | Switzerland | Metastatic Cancer | Infos |
| NCT00514930 | Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver | Interventional | Phase 1/Phase 2 | Unknown status | Greece | Liver Cancer | Infos |
| NCT00516347 | Studying Genes for Barrett's Esophagus in Brothers and Sisters | Observational | N/A | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00541021 | Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 3 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00544011 | Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00551057 | Expression of Inflammatory Proteins in Pancreatic Cancer | Observational | N/A | Unknown status | Switzerland | Pancreatic Neoplasms | Infos |
| NCT00559858 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Breast Cancer | Infos |
| NCT00559858 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00559858 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Palmar-plantar Erythrodysesthesia | Infos |
| NCT00560365 | Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00582257 | Early Onset and Familial Gastric Cancer Registry | Observational | N/A | Active but recruitment closed | Israel | Gastric Cancer | Infos |
| NCT00628368 | Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT00628368 | Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer | Interventional | Not Applicable | Unknown status | France | Esophageal Cancer | Infos |
| NCT00647530 | Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00669370 | Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Unknown status | Finland | Stomach Neoplasms | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Estonia | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Hungary | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Israel | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Italy | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Poland | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Turkey | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00690300 | Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Germany | Pancreas Neoplasms | Infos |
| NCT00693290 | Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00710632 | Screening to Predict Weight Loss in Patients With Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Gastrointestinal Cancer | Infos |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Israel | Colorectal Cancer | Infos |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Israel | Gastric Cancer | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Finland | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | France | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Germany | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Italy | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Spain | Gastrointestinal Stromal Tumors | Infos |
| NCT00757614 | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom | Observational | N/A | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00757614 | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom | Observational | N/A | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT00757965 | Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00758381 | Metastatic Advanced Pancreas Sorafenib | Interventional | Phase 2 | Unknown status | Italy | Locally Advanced Pancreatic Cancer | Infos |
| NCT00777478 | Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer | Interventional | Phase 1 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT00777504 | Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | Interventional | Phase 4 | Unknown status | Netherlands | Gastrointestinal Stromal Tumor | Infos |
| NCT00790140 | Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery | Interventional | Phase 4 | Unknown status | Ireland | Esophageal Cancer | Infos |
| NCT00797251 | Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression | Observational | N/A | Unknown status | Italy | Hepatocellular Carcinoma | Infos |
| NCT00797485 | Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00813696 | Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer | Interventional | Phase 3 | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Anxiety Disorder | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Cognitive/Functional Effects | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Colorectal Cancer | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Depression | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Excercise | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Fatigue | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Psychosocial Effects of Cancer and Its Treatment | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | France | Sleep Disorders | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Anxiety Disorder | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Cognitive/Functional Effects | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Depression | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Excercise | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Fatigue | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Psychosocial Effects of Cancer and Its Treatment | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | Not Applicable | Recruitment open | United Kingdom | Sleep Disorders | Infos |
| NCT00821912 | TaxXel: Taxotere and Xeloda in Esophageal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Norway | Cancer of the Esophagus | Infos |
| NCT00821912 | TaxXel: Taxotere and Xeloda in Esophageal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Norway | Gastric Cardia Carcinoma | Infos |
| NCT00821912 | TaxXel: Taxotere and Xeloda in Esophageal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Sweden | Cancer of the Esophagus | Infos |
| NCT00821912 | TaxXel: Taxotere and Xeloda in Esophageal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Sweden | Gastric Cardia Carcinoma | Infos |
| NCT00825110 | SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00838656 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT00838656 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Ovarian Cancer | Infos |
| NCT00838656 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Primary Peritoneal Cavity Cancer | Infos |
| NCT00845884 | Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Israel | Advanced Gastric Cancer | Infos |
| NCT00848952 | Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis | Interventional | Not Applicable | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Belgium | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Belgium | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Belgium | Metastatic Colorectal Cancer | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | France | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | France | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Italy | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Italy | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Portugal | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Portugal | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Portugal | Metastatic Colorectal Cancer | Infos |
| NCT00860691 | Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer | Interventional | Not Applicable | Unknown status | Croatia | Colonic Neoplasms | Infos |
| NCT00865982 | Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer | Interventional | Phase 2 | Unknown status | Germany | Esophageal Cancer | Infos |
| NCT00865982 | Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer | Interventional | Phase 2 | Unknown status | Germany | Gastric Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Iceland | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Latvia | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT00884767 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | Interventional | Phase 2 | Unknown status | France | Chemotherapeutic Agent Toxicity | Infos |
| NCT00884767 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00884767 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | Interventional | Phase 2 | Unknown status | France | Neurotoxicity | Infos |
| NCT00888797 | Ī²-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence | Interventional | Phase 3 | Unknown status | Israel | Colorectal Neoplasms | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Austria | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Denmark | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Germany | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Netherlands | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Spain | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Sweden | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Switzerland | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | United Kingdom | Colon Cancer | Infos |
| NCT00906997 | Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy | Interventional | Phase 3 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT00906997 | Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy | Interventional | Phase 3 | Unknown status | Spain | Colorectal Neoplasm | Infos |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | Interventional | Phase 2 | Unknown status | Israel | Metastatic Colorectal Cancer | Infos |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | Interventional | Phase 2 | Unknown status | Netherlands | Metastatic Colorectal Cancer | Infos |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | Interventional | Phase 2 | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT00934505 | Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus Carcinoma | Observational | N/A | Unknown status | France | Oesophageal Cancer | Infos |
| NCT00947102 | Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer | Observational | N/A | Unknown status | Slovenia | Pancreatic Tubular Adenocarcinoma | Infos |
| NCT00958737 | Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT00963092 | Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | Observational | N/A | Unknown status | United Kingdom | Adenocarcinoma of the Gastroesophageal Junction | Infos |
| NCT00963092 | Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | Observational | N/A | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT00963092 | Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | Observational | N/A | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT00963352 | Colon Cancer Prognosis After Radical Surgery | Observational | N/A | Unknown status | Norway | Colon Cancer | Infos |
| NCT00964171 | Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00964457 | Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Denmark | Rectum Cancer | Infos |
| NCT00973869 | Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery | Interventional | Phase 1 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00987857 | Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus | Interventional | Not Applicable | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Belgium | Pancreatic Adenocarcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Belgium | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Belgium | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Belgium | Stage II Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Belgium | Stage I Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Pancreatic Adenocarcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Stage II Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Stage I Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | Interventional | Phase 2 | Unknown status | Cyprus | Digestive System Neoplasms | Infos |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | Interventional | Phase 2 | Unknown status | United Kingdom | Digestive System Neoplasms | Infos |
| NCT01038154 | Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer | Interventional | Phase 4 | Unknown status | Spain | Esophageal Cancer | Infos |
| NCT01038154 | Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer | Interventional | Phase 4 | Unknown status | Spain | Stomach Cancer | Infos |
| NCT01044511 | Quality of Life With Esophageal Stent Trial | Interventional | Not Applicable | Unknown status | Denmark | Esophageal Cancer | Infos |
| NCT01048216 | Partial Liver Radiotherapy for Unresectable Liver Metastases | Interventional | Not Applicable | Unknown status | United Kingdom | Metastatic Colorectal Liver Cancer | Infos |
| NCT01056796 | Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CARā¢ 27 | Interventional | Phase 2 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT01062334 | Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer | Interventional | Not Applicable | Unknown status | Denmark | Cancer | Infos |
| NCT01067053 | Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. | Interventional | Phase 2 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01071824 | Comparison of Limb Size of Transverse Coloplasty Pouch | Interventional | Not Applicable | Recruitment open | Switzerland | Colon Cancer | Infos |
| NCT01073358 | Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy | Interventional | Not Applicable | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT01087268 | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01097265 | Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01110785 | Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01110798 | J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the Tumor | Interventional | Not Applicable | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01144195 | A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ā„ 6 Months After the Last Dose of the First Line Chemotherapy | Interventional | Phase 2 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01160419 | Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer | Interventional | Phase 2 | Unknown status | Germany | Gastric Cancer | Infos |
| NCT01182246 | AXP107-11 in Combination With Standard Gemcitabine (GemzarĀ® ) Therapy for Treatment in Patients With Pancreatic Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Sweden | Adenocarcinoma | Infos |
| NCT01182272 | Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery | Interventional | Phase 2 | Unknown status | France | Liver Cancer | Infos |
| NCT01183156 | Re-invitation to Screening Colonoscopy: a Randomized Study | Interventional | Not Applicable | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT01190462 | Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01214681 | Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01226394 | Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer With a Resected Minimal Synchronous PC | Infos |
| NCT01230697 | Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | Observational | N/A | Unknown status | Italy | Kidney Cancer | Infos |
| NCT01230697 | Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | Observational | N/A | Unknown status | Italy | Liver Cancer | Infos |
| NCT01234246 | Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners. | Observational | N/A | Unknown status | Netherlands | Colorectal Cancer Patients and Their Partners | Infos |
| NCT01236989 | Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC | Interventional | Not Applicable | Unknown status | Italy | Patients Affected by Hepatocellular Carcinoma | Infos |
| NCT01249638 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer Metastatic | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Breast Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Head and Neck Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | Not Applicable | Unknown status | United Kingdom | Lung Cancer | Infos |
| NCT01272557 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | Interventional | Phase 2 | Unknown status | Germany | Liver Carcinoma | Infos |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT | Observational | N/A | Active but recruitment closed | Finland | Peritoneal Cancer | Infos |
| NCT01279278 | Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT01279330 | Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT01286064 | Colorectal Cancer Detection by Means of Optical Fluoroscopy | Interventional | Not Applicable | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01292369 | Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study | Observational | N/A | Unknown status | Israel | Breast Cancer | Infos |
| NCT01292369 | Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study | Observational | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT01292681 | Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer | Interventional | Not Applicable | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01308086 | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer | Interventional | Phase 3 | Unknown status | Greece | CRC | Infos |
| NCT01315990 | FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema | Interventional | Phase 4 | Unknown status | Germany | Colorectal Cancer Metastatic | Infos |
| NCT01320319 | Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01322477 | Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency | Observational | N/A | Unknown status | Israel | Hepatocellular Carcinoma | Infos |
| NCT01324076 | Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | Interventional | Phase 3 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT01324856 | Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy | Interventional | Phase 1 | Unknown status | Serbia | Pancreatic Cancer | Infos |
| NCT01330186 | Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy | Observational | N/A | Unknown status | Denmark | Anal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | France | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | France | Pancreatic Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Germany | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Germany | Pancreatic Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Italy | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Italy | Pancreatic Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Netherlands | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Pancreatic Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Spain | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Active but recruitment closed | Spain | Pancreatic Cancer | Infos |
| NCT01351714 | Safe D3 Right Hemicolectomy for Cancer Through Multidetector Computed Tomography (MDCT) Angio | Interventional | Not Applicable | Unknown status | Norway | Colon Cancer | Infos |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Adenocarcinoma of the Gastro-oesophageal Junction | Infos |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Metastatic Gastric Cancer | Infos |
| NCT01363739 | Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab | Observational | N/A | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01372735 | Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Pancreatic Neoplasms | Infos |
| NCT01377220 | Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma | Interventional | Phase 2 | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01380262 | Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment | Observational | N/A | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Germany | After Resection of Liver Metastases | Infos |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Germany | KRAS Wildtype | Infos |
| NCT01394120 | Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Spain | Carcinoma, Pancreatic Ductal | Infos |
| NCT01410760 | PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases | Interventional | Early Phase 1 | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT01441453 | Transient Elastography in Hepatectomy for Hepatocellular Carcinoma | Interventional | Not Applicable | Unknown status | Italy | Hepatocellular Carcinoma | Infos |
| NCT01441453 | Transient Elastography in Hepatectomy for Hepatocellular Carcinoma | Interventional | Not Applicable | Unknown status | Italy | Surgery | Infos |
| NCT01442324 | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | Interventional | Not Applicable | Unknown status | Italy | Cholangiocarcinoma | Infos |
| NCT01442324 | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | Interventional | Not Applicable | Unknown status | Italy | Metastatic Liver Cancer | Infos |
| NCT01442324 | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | Interventional | Not Applicable | Unknown status | Italy | Neoplasm Metastasis | Infos |
| NCT01444755 | The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer | Observational | N/A | Unknown status | Turkey | Gastric Cancer | Infos |
| NCT01448655 | Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT01448655 | Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT01448668 | Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Austria | Pancreas Cancer | Infos |
| NCT01448668 | Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Germany | Pancreas Cancer | Infos |
| NCT01456455 | Gastric Cancer Metastasized to the Central Nervous System (CNS) | Observational | N/A | Unknown status | Switzerland | Gastric Cancer | Infos |
| NCT01458353 | Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Intra-abdominal Abscess | Infos |
| NCT01458353 | Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Peritoneal Contamination After Ileocolonic Anastomosis | Infos |
| NCT01458353 | Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Wound Infection | Infos |
| NCT01470235 | Hypodontia and Ovarian Cancer | Observational | N/A | Unknown status | Denmark | Colon Cancer | Infos |
| NCT01479608 | Liver Transplantation and Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT01479608 | Liver Transplantation and Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Norway | Liver Metastasis | Infos |
| NCT01492127 | Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment | Interventional | Not Applicable | Unknown status | France | Cirrhosis | Infos |
| NCT01492127 | Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment | Interventional | Not Applicable | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01509911 | A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment | Interventional | Phase 2 | Unknown status | Israel | Metastatic Pancreatic Cancer | Infos |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Colorectal Cancer | Infos |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Switzerland | Colorectal Cancer | Infos |
| NCT01531595 | Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Finland | Metastatic Colorectal Cancer | Infos |
| NCT01531621 | A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland | Observational | N/A | Recruitment open | Finland | Metastatic Colorectal Cancer | Infos |
| NCT01538550 | Pilot Study of a National Screening Programme for Bowel Cancer in Norway | Interventional | Not Applicable | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT01563133 | Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas | Interventional | Not Applicable | Unknown status | France | Pancreatic Cancer | Infos |
| NCT01570010 | Effect of Norwegian Food Based Dietary Guidelines on Chronic Diseases in CRC Survivors | Interventional | Not Applicable | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT01573468 | Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer | Interventional | Phase 2 | Unknown status | Germany | Gastric Carcinoma | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Locally Advanced Pancreatic Adenocarcinoma | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Metastatic Pancreatic Adenocarcinoma | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Stage III Pancreatic Cancer AJCC v8 | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Stage IV Pancreatic Cancer AJCC v8 | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | From Surgery in the Two Study Groups. | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | Prophylaxis Given for 8Ā±2 Days After Planned Laparoscopic | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | Safety of Extended 4-week Heparin Prophylaxis Compared to | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | Surgery for Colorectal Cancer. | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | The Clinical Benefit Will be Evaluated as the Difference in | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | the Incidence of VTE or VTE-related Death Occurring Within 30 Days | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | The Primary Study Objective is to Assess the Efficacy and | Infos |
| NCT01601808 | Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma | Interventional | Phase 2 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT01626963 | Single-port Versus Conventional Laparoscopic Colorectal Surgery | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01628211 | Second Look Laparoscopy in Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Italy | Colorectal Cancer | Infos |
| NCT01639326 | Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 | Interventional | Phase 2 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01641003 | Isolation and Characterization of Cancer Stem Cells Using iFP Technique | Observational | N/A | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01642875 | Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy | Interventional | Phase 4 | Unknown status | Poland | Pancreatic Cancer | Infos |
| NCT01651013 | Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras | Observational | N/A | Active but recruitment closed | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01651026 | Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer | Observational | N/A | Recruitment open | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT01659502 | Investigator's Initiated Phase II Study for Pancreatic Cancer Patients | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01662739 | Cremona Population-Based Gastric Tumors Registry | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT01673607 | Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Resectable Hepatic Metastases of Colorectal Cancer | Infos |
| NCT01675258 | Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers | Observational | N/A | Unknown status | Israel | Colorectal Cancer and Pre-cancer Polyps | Infos |
| NCT01675258 | Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers | Observational | N/A | Unknown status | Israel | Gastric Cancer | Infos |
| NCT01675258 | Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers | Observational | N/A | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01675505 | Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery | Observational | N/A | Unknown status | Greece | Adaptation, Psychological | Infos |
| NCT01675505 | Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery | Observational | N/A | Unknown status | Greece | Functional Insufficiency | Infos |
| NCT01675999 | Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer | Interventional | Phase 2 | Unknown status | France | Colon Cancer | Infos |
| NCT01675999 | Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer | Interventional | Phase 2 | Unknown status | France | Locally Advanced Malignant Neoplasm | Infos |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01679756 | INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer | Interventional | Not Applicable | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01686971 | The Needs of Cancer Survivors | Observational | N/A | Unknown status | Israel | Colon Cancer Patients. | Infos |
| NCT01688232 | The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer | Observational | N/A | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT01688232 | The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer | Observational | N/A | Active but recruitment closed | France | Surgical Resection of the Colorectal Tumor | Infos |
| NCT01704664 | Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients | Interventional | Not Applicable | Unknown status | Poland | Gastric Cancer | Infos |
| NCT01706809 | Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer | Observational | N/A | Unknown status | Denmark | Rectal Cancer | Infos |
| NCT01707511 | The Investigation of the EtCOā- PaCOā Relation During Laparoscopic Colon Surgery | Observational | N/A | Unknown status | Turkey | Colorectal Cancer | Infos |
| NCT01713218 | Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer | Interventional | Early Phase 1 | Unknown status | Belgium | Pancreatic Adenocarcinoma Resectable | Infos |
| NCT01715402 | Optimization of Health Expenditure in Liver Surgery | Observational | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01717196 | Diagnostic Accuracy of FNA: is Aspiration- Related? | Interventional | Not Applicable | Unknown status | Italy | PANCREATIC CANCER | Infos |
| NCT01717807 | C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR). | Observational | N/A | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01726010 | 22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract | Interventional | Not Applicable | Unknown status | Germany | Subepithelial Tumors of the Upper Gastrointestinal Tract | Infos |
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Germany | Metastatic Pancreatic Adenocarcinoma | Infos |
| NCT01731366 | The Effect of Whole Grain on Gut Microbiome and Metabolic Health | Interventional | Not Applicable | Unknown status | Denmark | Injury of Gastrointestinal Tract | Infos |
| NCT01744509 | PillCam Colon Capsule 2Ā® (PCC2) in the Setting of Colorectal Cancer Screening Program | Interventional | Not Applicable | Unknown status | Italy | Colon Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Austria | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Belgium | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Denmark | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Estonia | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Germany | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Greece | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Netherlands | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Norway | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Romania | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Russian Federation | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Sweden | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT01761097 | Endocuff Adenoma Detection Rate Pilot Study | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01762813 | Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer | Observational | N/A | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT01779583 | Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study") | Observational | N/A | Unknown status | Spain | Gastric Cancer | Infos |
| NCT01786122 | Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients | Interventional | Not Applicable | Unknown status | Spain | Digestive System Neoplasms | Infos |
| NCT01786200 | Physiological Effects of Altering Cancer-related Inflammation | Interventional | Not Applicable | Unknown status | United Kingdom | Colon Cancer | Infos |
| NCT01787539 | The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Poland | Gastric Cancer | Infos |
| NCT01792934 | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases | Interventional | Not Applicable | Recruitment open | Netherlands | Multi-organ Metastatic Colorectal Cancer | Infos |
| NCT01792934 | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases | Interventional | Not Applicable | Recruitment open | United Kingdom | Multi-organ Metastatic Colorectal Cancer | Infos |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | Interventional | Phase 2 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | Interventional | Phase 2 | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT01801904 | A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01802645 | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT01814150 | The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | Observational | N/A | Unknown status | Israel | Metastatic Gastric Cancer | Infos |
| NCT01827553 | Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Germany | Pancreatic Cancer | Infos |
| NCT01843829 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT01853059 | Functional Outcomes Following Anal Cancer Treatment | Observational | N/A | Unknown status | United Kingdom | Anal Cancer | Infos |
| NCT01879878 | Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] | Interventional | Not Applicable | Unknown status | Germany | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT01891539 | Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma | Observational | N/A | Unknown status | Italy | Liver Cell Carcinoma Non-resectable | Infos |
| NCT01895257 | Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer | Interventional | Phase 3 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT01898104 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Italy | Colorectal Cancer | Infos |
| NCT01898741 | Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer Metastatic | Infos |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | Ireland | Colorectal Cancer Metastatic | Infos |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | Israel | Colorectal Cancer Metastatic | Infos |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Colon Cancer | Infos |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | Colon Cancer | Infos |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | Interventional | Phase 3 | Active but recruitment closed | Sweden | Colon Cancer | Infos |
| NCT01919151 | Micrometastasis in Gastrointestinal Cancer | Observational | N/A | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT01919151 | Micrometastasis in Gastrointestinal Cancer | Observational | N/A | Unknown status | Norway | Pancreatic Adenocarcinoma | Infos |
| NCT01927328 | Iron Replacement in Oesophagogastric Neoplasia | Interventional | Phase 4 | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT01927328 | Iron Replacement in Oesophagogastric Neoplasia | Interventional | Phase 4 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT01937429 | Effectiveness of Instillation of Blue Water (Indigo CarminĀ®) for Colonoscopy | Interventional | Phase 3 | Unknown status | France | Adenoma Detection to Prevent Colorectal Cancer | Infos |
| NCT01937780 | Anal Cancer Radiotherapy Study | Observational | N/A | Active but recruitment closed | Norway | Anal Cancer | Infos |
| NCT01943786 | RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab | Observational | N/A | Unknown status | Spain | Colorectal Cancer Metastatic | Infos |
| NCT01945723 | Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers | Observational | N/A | Unknown status | Israel | Healthy | Infos |
| NCT01958697 | Age and Gender Corrected Body Mass Index | Observational | N/A | Unknown status | Belgium | Esophageal Cancer | Infos |
| NCT01959906 | Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer. | Observational | N/A | Unknown status | Belgium | Esophageal Cancer | Infos |
| NCT01964534 | Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Metastatic Pancreatic Cancer | Infos |
| NCT01966081 | AGARIC Case Control Study | Interventional | Not Applicable | Unknown status | France | First Recently-diagnosed Colorectal Cancer | Infos |
| NCT01983098 | Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment | Observational | N/A | Unknown status | France | To Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan. | Infos |
| NCT01991080 | The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy | Interventional | Not Applicable | Unknown status | Israel | Colon Cancer | Infos |
| NCT01995942 | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | Observational | N/A | Unknown status | United Kingdom | Digestive System Neoplasms | Infos |
| NCT02002195 | Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer | Observational | N/A | Unknown status | Italy | Metastatic Gastric Cancer | Infos |
| NCT02002299 | Does Surface Tell us About the Invasive Front in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT02005965 | Low Rectal Cancer Study (MERCURY II) | Observational | N/A | Unknown status | Germany | Digestive System Neoplasms | Infos |
| NCT02005965 | Low Rectal Cancer Study (MERCURY II) | Observational | N/A | Unknown status | Serbia | Digestive System Neoplasms | Infos |
| NCT02005965 | Low Rectal Cancer Study (MERCURY II) | Observational | N/A | Unknown status | United Kingdom | Digestive System Neoplasms | Infos |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | Interventional | Phase 2 | Unknown status | Italy | Gastric Adenocarcinoma | Infos |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | Interventional | Phase 2 | Unknown status | Italy | Gastroesophageal Junction Adenocarcinoma | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Anal Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Colon Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Esophageal Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Familial Adenomatous Polyposis | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Liver Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Lynch Syndrome | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Pancreatic Cancer | Infos |
| NCT02017366 | Design of the EFECTS Trial | Interventional | Not Applicable | Unknown status | Belgium | Esophageal Cancer | Infos |
| NCT02024009 | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Pancreatic Neoplasms (Locally Advanced Non-metastatic) | Infos |
| NCT02039336 | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02045680 | RADOX' Reduced Abdominal Distension and Oxygen Delivery | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality | Interventional | Phase 4 | Recruitment open | Latvia | Atrophic Gastritis | Infos |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality | Interventional | Phase 4 | Recruitment open | Latvia | Gastric Cancer | Infos |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality | Interventional | Phase 4 | Recruitment open | Latvia | Helicobacter Pylori Infections | Infos |
| NCT02051283 | Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCC | Observational | N/A | Unknown status | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02051868 | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | Interventional | Phase 2 | Unknown status | United Kingdom | Squamous Cell Carcinoma of the Anus | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Gastric Cancer | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Gastric Cancer | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Portugal | Gastric Cancer | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Gastric Cancer | Infos |
| NCT02053805 | Prostate Cancer Screening Among Men With High Risk Genetic Predisposition | Interventional | Not Applicable | Unknown status | Israel | Lynch Syndrome | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02066259 | OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol | Observational | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT02070146 | Prospective Data Collection Initiative on Colorectal Cancer | Observational | N/A | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02075086 | Angiogenic Switch in Patients With Colorectal Cancer | Interventional | Phase 2 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | Austria | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | Belgium | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | Estonia | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | Germany | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT02078245 | Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer. | Observational | N/A | Recruitment open | Sweden | Hereditary Pancreatic Cancer | Infos |
| NCT02078245 | Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer. | Observational | N/A | Recruitment open | Sweden | Hereditary Pancreatitis | Infos |
| NCT02079363 | DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatic Diseases | Infos |
| NCT02079363 | DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatic Neoplasms | Infos |
| NCT02079363 | DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatitis | Infos |
| NCT02089269 | Tumor Registry Pancreatic Cancer | Observational | N/A | Active but recruitment closed | Germany | Pancreas Cancer | Infos |
| NCT02112357 | Feasibility of a Molecular Characterisation Approach to Treatment | Observational | N/A | Unknown status | United Kingdom | Advanced Gastrointestinal Cancers | Infos |
| NCT02125409 | Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action | Interventional | Phase 3 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02138370 | Comprehensive Immune-landscape in Localized Colorectal Cancer | Observational | N/A | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT02138370 | Comprehensive Immune-landscape in Localized Colorectal Cancer | Observational | N/A | Unknown status | Switzerland | Immune Landscape | Infos |
| NCT02145013 | Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma | Observational | N/A | Unknown status | France | Primary Liver Cancers | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Belgium | Liver Metastases | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Netherlands | Liver Metastases | Infos |
| NCT02164149 | Length of Tumour Feeding Artery After Colon Cancer Surgery | Observational | N/A | Unknown status | Denmark | Colon Cancer | Infos |
| NCT02175914 | Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis | Interventional | Phase 4 | Unknown status | Israel | FAP-Familial Adenomatous Polyposis | Infos |
| NCT02184663 | Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer | Interventional | Not Applicable | Active but recruitment closed | France | Metastatic Pancreatic Cancer | Infos |
| NCT02184663 | Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer | Interventional | Not Applicable | Active but recruitment closed | France | Unresectable Locally Advanced Cancer | Infos |
| NCT02188927 | Effect of an Advanced Notification Letter on Screening Colonoscopy Participation | Interventional | Not Applicable | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT02197351 | Narrow Band Imaging for Gastric Neoplasia | Interventional | Not Applicable | Recruitment open | Portugal | Gastric Cancer | Infos |
| NCT02208804 | Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Digestive System Neoplasms | Infos |
| NCT02209415 | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Denmark | Esophageal Cancer | Infos |
| NCT02209415 | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Denmark | Pancreatic Cancer | Infos |
| NCT02209415 | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Denmark | Stomach Cancer | Infos |
| NCT02215577 | ALPPS Versus PVE/PL | Interventional | Not Applicable | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT02215577 | ALPPS Versus PVE/PL | Interventional | Not Applicable | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT02215577 | ALPPS Versus PVE/PL | Interventional | Not Applicable | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT02215889 | Partial Liver Segment 2/3 Transplantation Study | Interventional | Phase 1/Phase 2 | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02231385 | Acetic Acid Colonoscopy Enhancement Study | Interventional | Not Applicable | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02246322 | A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. | Interventional | Not Applicable | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | Interventional | Not Applicable | Recruitment open | United Kingdom | Colorectal Neoplasms | Infos |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | Interventional | Not Applicable | Recruitment open | United Kingdom | Hepatic Neoplasms | Infos |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | Interventional | Not Applicable | Recruitment open | United Kingdom | Neoplasm Metastases | Infos |
| NCT02246725 | Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial. | Observational | N/A | Unknown status | Sweden | Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer | Infos |
| NCT02248519 | Laparoscopic Versus Open Gastrectomy for Gastric Cancer | Interventional | Not Applicable | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT02254941 | Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer | Observational | N/A | Active but recruitment closed | Spain | Metastatic Colon Cancer | Infos |
| NCT02260128 | Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery | Interventional | Not Applicable | Unknown status | Denmark | Pancreatic Cancer | Infos |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | Interventional | Phase 3 | Recruitment open | France | Gastrointestinal Stromal Tumors | Infos |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | Interventional | Phase 3 | Recruitment open | France | Resected Gastrointestinal Stromal Tumors | Infos |
| NCT02274753 | Personalizing Colorectal Cancer Medicine (ImmuCol2) | Observational | N/A | Active but recruitment closed | France | Colon Cancer | Infos |
| NCT02296203 | Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02299596 | Physical Activity in Relation to Surgical Procedures | Interventional | Not Applicable | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Adjuvant Therapy | Infos |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Colon Cancer | Infos |
| NCT02304978 | Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults | Interventional | Early Phase 1 | Unknown status | France | Colorectal Cancer | Infos |
| NCT02325323 | Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia | Observational | N/A | Unknown status | France | Stomach Cancer | Infos |
| NCT02325453 | Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT02327494 | Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery | Observational | N/A | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02327819 | The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer | Interventional | Not Applicable | Unknown status | Israel | Primary Liver Cancer | Infos |
| NCT02328677 | ColoCare Study - Colorectal Cancer Cohort | Observational | N/A | Recruitment open | Germany | Colorectal Cancer | Infos |
| NCT02331927 | PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Germany | Metastatic Colorectal Cancer | Infos |
| NCT02339116 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC | Interventional | Phase 3 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02355119 | Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer | Interventional | Phase 3 | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT02356406 | Celiac Plexus Radiosurgery for Pain Management | Interventional | Phase 2 | Unknown status | Israel | Digestive System Neoplasms | Infos |
| NCT02363049 | Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer | Interventional | Phase 3 | Unknown status | France | Colon Cancer Liver Metastasis | Infos |
| NCT02363049 | Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer | Interventional | Phase 3 | Unknown status | France | Malignant Neoplasm of Large Intestine | Infos |
| NCT02372500 | Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02379039 | Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer | Observational | N/A | Unknown status | Sweden | Anal Cancer | Infos |
| NCT02379039 | Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer | Observational | N/A | Unknown status | Sweden | Esophageal Cancer | Infos |
| NCT02395224 | A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway | Observational | N/A | Active but recruitment closed | Norway | Neoplasm Metastasis | Infos |
| NCT02395224 | A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway | Observational | N/A | Active but recruitment closed | Norway | Neoplasms, Colorectal | Infos |
| NCT02403050 | Feasibility Study of Fiducial Markers in Oesophageal Cancer | Observational | N/A | Unknown status | United Kingdom | Esophageal Neoplasms | Infos |
| NCT02415101 | Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer | Interventional | Not Applicable | Active but recruitment closed | Sweden | Cancer of the Esophagus | Infos |
| NCT02416609 | Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer | Interventional | Not Applicable | Recruitment open | Italy | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Poland | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Poland | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Spain | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Spain | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT02424279 | Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder | Interventional | Not Applicable | Unknown status | Poland | Pain | Infos |
| NCT02424279 | Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder | Interventional | Not Applicable | Unknown status | Poland | Pancreatic Cancer | Infos |
| NCT02425657 | Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments | Observational | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT02436564 | In Vitro Models of Liver and Pancreatic Cancer | Observational | N/A | Unknown status | United Kingdom | Cholangiocarcinoma | Infos |
| NCT02436564 | In Vitro Models of Liver and Pancreatic Cancer | Observational | N/A | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02436564 | In Vitro Models of Liver and Pancreatic Cancer | Observational | N/A | Unknown status | United Kingdom | Pancreatic Neoplasm | Infos |
| NCT02443948 | Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) | Observational | N/A | Unknown status | Italy | Gastrointestinal Stromal Tumor (GIST) | Infos |
| NCT02454790 | Standard Follow-Up Program (SFP) for Patients With Esophageal Cancer | Observational | N/A | Recruitment open | Netherlands | Esophageal Cancer | Infos |
| NCT02457156 | Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Pancreatic Cancer | Infos |
| NCT02458664 | BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer | Observational | N/A | Unknown status | France | Cancer of Colon | Infos |
| NCT02458664 | BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer | Observational | N/A | Unknown status | France | Rectum Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Belgium | Colon Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Germany | Colon Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Hungary | Colon Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Switzerland | Colon Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Ovarian Neoplasm | Infos |
| NCT02476045 | Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02497820 | Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers | Interventional | Phase 3 | Not yet recruiting | Israel | Lynch Syndrome I (Site-specific Colonic Cancer) | Infos |
| NCT02502656 | RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Germany | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Switzerland | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02512263 | Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer Patients | Interventional | Not Applicable | Unknown status | Belgium | Colon Cancer | Infos |
| NCT02513849 | Tamoxifen in Patients With Oesophageal Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Cancer | Infos |
| NCT02513849 | Tamoxifen in Patients With Oesophageal Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Gastrointestinal Neoplasms | Infos |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | Interventional | Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | Interventional | Phase 2 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT02519582 | Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT02526264 | Evaluation of Quality of Life and Period of Hospitalization by Education | Interventional | Not Applicable | Recruitment open | Germany | Colorectal Cancer | Infos |
| NCT02526836 | Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Italy | Colon Cancer | Infos |
| NCT02530593 | QoLiCOL - Quality of Life in Colon Cancer | Observational | N/A | Active but recruitment closed | Sweden | Colonic Neoplasm | Infos |
| NCT02539537 | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | Interventional | Phase 3 | Active but recruitment closed | France | Pancreatic Cancer | Infos |
| NCT02545699 | Prospective Trial to Compare ADR of G-EYEā¢ Colonoscopy With Standard Colonoscopy | Interventional | Not Applicable | Unknown status | Israel | Colorectal Cancer | Infos |
| NCT02546973 | Quality of Life in Patients With Anal Cancer | Observational | N/A | Active but recruitment closed | Sweden | Anal Cancer | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Unknown status | France | Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Unknown status | France | Adenocarcinoma of the Thoracic Oesophagus or | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Unknown status | France | Epidermoid Carcinoma or | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Unknown status | France | Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 | Infos |
| NCT02556281 | Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III | Interventional | Not Applicable | Unknown status | France | Colorectal Neoplasms | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Belgium | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | France | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Germany | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Italy | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Netherlands | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Poland | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Poland | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | Spain | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Pancreatic Cancer | Infos |
| NCT02574013 | Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal Surgery | Interventional | Not Applicable | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Belgium | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Czechia | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Denmark | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | France | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Germany | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Greece | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Hungary | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Ireland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Italy | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Norway | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Poland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Portugal | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Russian Federation | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Slovakia | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Spain | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Sweden | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Turkey | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Ukraine | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | United Kingdom | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Austria | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Czechia | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Israel | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Sweden | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02577627 | Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC | Observational | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT02578368 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | Interventional | Phase 3 | Recruitment open | Germany | Gastric Cancer | Infos |
| NCT02579278 | Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion | Observational | N/A | Recruitment open | United Kingdom | Cancer | Infos |
| NCT02579278 | Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion | Observational | N/A | Recruitment open | United Kingdom | Rectal Cancer | Infos |
| NCT02591667 | Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | Interventional | Phase 2 | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT02591667 | Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | Interventional | Phase 2 | Unknown status | Austria | Peritoneal Metastasis | Infos |
| NCT02597348 | Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy | Interventional | Not Applicable | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02614534 | Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT02618850 | PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment | Interventional | Not Applicable | Active but recruitment closed | Italy | Colorectal Cancer Stage IV | Infos |
| NCT02619435 | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Italy | Advanced Colorectal Cancer | Infos |
| NCT02624271 | Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk | Interventional | Not Applicable | Unknown status | France | Gastric Cancer | Infos |
| NCT02624271 | Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk | Interventional | Not Applicable | Unknown status | France | Gastric Precancerous Lesions | Infos |
| NCT02624726 | Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | Interventional | Phase 2 | Unknown status | Greece | Metastatic Colorectal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Denmark | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | France | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Germany | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Israel | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Italy | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Netherlands | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Norway | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Russian Federation | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Spain | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | United Kingdom | Anal Cancer | Infos |
| NCT02633098 | A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer | Interventional | Phase 2 | Recruitment open | United Kingdom | Bowel Cancer | Infos |
| NCT02633098 | A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer | Interventional | Phase 2 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Czechia | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Denmark | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Ireland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Israel | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Poland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Russian Federation | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Sweden | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Switzerland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Turkey | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Ukraine | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02646462 | Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatic Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Denmark | Colorectal Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Finland | Colorectal Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Sweden | Colorectal Cancer | Infos |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Metastatic Colorectal Cancer (mCRC) | Infos |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Metastatic Colorectal Cancer (mCRC) | Infos |
| NCT02665312 | Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02668913 | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Peritoneal Cancer | Infos |
| NCT02672774 | Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers | Interventional | Not Applicable | Unknown status | Romania | Colorectal Cancer | Infos |
| NCT02672774 | Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers | Interventional | Not Applicable | Unknown status | Romania | Gastric Cancer | Infos |
| NCT02672774 | Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers | Interventional | Not Applicable | Unknown status | Romania | Gastrointestinal Neoplasms | Infos |
| NCT02674100 | American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | Observational | N/A | Active but recruitment closed | United Kingdom | Pancreatic Cancer | Infos |
| NCT02674373 | Prognostic and Predictive Impact of Circulating Tumor DNA in Gastric Cancer Treatment | Observational | N/A | Unknown status | France | Gastric Cancer | Infos |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Interventional | Phase 2 | Recruitment open | United Kingdom | Adenocarcinoma of the Gastro-oesophageal Junction | Infos |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Interventional | Phase 2 | Recruitment open | United Kingdom | Adenocarcinoma of the Oesophagus | Infos |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Interventional | Phase 2 | Recruitment open | United Kingdom | Adenocarcinoma of the Stomach | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Czechia | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Hungary | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Poland | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Slovakia | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Spain | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Ukraine | Ovarian Neoplasms | Infos |
| NCT02697084 | Individual Following in Anal Cancer With PET/CT | Observational | N/A | Unknown status | France | Anal Cancer | Infos |
| NCT02701088 | Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life | Interventional | Phase 2 | Active but recruitment closed | France | Locally Advanced Anal Canal Cancer | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Sweden | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT02705300 | Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Denmark | Colorectal Cancer | Infos |
| NCT02707796 | Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index | Interventional | Not Applicable | Unknown status | Turkey | COLON CANCER | Infos |
| NCT02715882 | Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer | Interventional | Phase 2 | Unknown status | Russian Federation | Colorectal Cancer | Infos |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT02726243 | Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02726243 | Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease | Observational | N/A | Unknown status | France | Inflammatory Bowel Disease | Infos |
| NCT02732301 | Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers | Observational | N/A | Unknown status | Sweden | Gastrointestinal Tract | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Israel | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Switzerland | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Gastric Cancers | Infos |
| NCT02738359 | Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening | Observational | N/A | Recruitment open | France | Colon Cancer | Infos |
| NCT02738359 | Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening | Observational | N/A | Recruitment open | France | Rectum Cancer | Infos |
| NCT02741167 | Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Observational | N/A | Unknown status | Switzerland | Peritoneal Cancer | Infos |
| NCT02741856 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | Not Applicable | Unknown status | Austria | Hepatocellular Carcinoma | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | Not Applicable | Unknown status | Finland | Hepatocellular Carcinoma | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | Not Applicable | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | Not Applicable | Unknown status | Netherlands | Hepatocellular Carcinoma | Infos |
| NCT02748551 | A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer | Interventional | Phase 3 | Unknown status | Russian Federation | Gastric Cancer | Infos |
| NCT02748551 | A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer | Interventional | Phase 3 | Unknown status | Ukraine | Gastric Cancer | Infos |
| NCT02751086 | Robotic, Laparoscopic and Open Gastrectomy Compared on Short and Long Term Outcomes | Observational | N/A | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT02756455 | Procalcitonin Reveals Early Dehiscence in Gastric Surgery: the PREDIGS Study | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT02756468 | Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study | Observational | N/A | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | Belgium | Peritoneal Cancer | Infos |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | Netherlands | Peritoneal Cancer | Infos |
| NCT02758977 | Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) | Interventional | Not Applicable | Unknown status | Switzerland | Colon Cancer Liver Metastases | Infos |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02767557 | Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | Interventional | Phase 2 | Active but recruitment closed | Denmark | Unresectable Pancreatic Carcinoma | Infos |
| NCT02767557 | Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | Interventional | Phase 2 | Active but recruitment closed | Norway | Unresectable Pancreatic Carcinoma | Infos |
| NCT02780921 | Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial | Interventional | Phase 3 | Unknown status | France | Gastric Cancer | Infos |
| NCT02780921 | Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial | Interventional | Phase 3 | Unknown status | France | Oesophageal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | Austria | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | Austria | Colorectal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | Belgium | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | France | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | Poland | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Active but recruitment closed | Poland | Colorectal Cancer | Infos |
| NCT02785263 | Shared Decision Making With Anal Cancer Patients on Radiation Dose | Interventional | Not Applicable | Active but recruitment closed | Denmark | Anal Cancer | Infos |
| NCT02786329 | Anesthesia and Postoperative Outcome in Colorectal Cancer Patients | Interventional | Early Phase 1 | Recruitment open | Romania | Colorectal Cancer | Infos |
| NCT02786342 | Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib | Observational | N/A | Unknown status | Italy | Hepatocellular Carcinoma | Infos |
| NCT02788669 | LRP1 and Colon Cancer | Observational | N/A | Unknown status | France | Adenocarcinoma | Infos |
| NCT02788669 | LRP1 and Colon Cancer | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT02789709 | Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers | Observational | N/A | Unknown status | Spain | Colon Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Belgium | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | France | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Israel | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Spain | Pancreatic Cancer | Infos |
| NCT02792023 | Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT) | Interventional | Not Applicable | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Georgia | Adenocarcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Georgia | Gastrointestinal Neoplasms | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Serbia | Adenocarcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Serbia | Gastrointestinal Neoplasms | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Ukraine | Adenocarcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Ukraine | Gastrointestinal Neoplasms | Infos |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | Observational | N/A | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma | Interventional | Phase 3 | Recruitment open | France | Hepatocellular Carcinoma | Infos |
| NCT02804802 | Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer Screening | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | Ireland | Colorectal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | Ireland | Gastro-oesophageal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | United Kingdom | Gastro-oesophageal Cancer | Infos |
| NCT02811666 | Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers | Interventional | Not Applicable | Unknown status | France | Liver Cancer | Infos |
| NCT02811666 | Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers | Interventional | Not Applicable | Unknown status | France | Pancreatic Cancer | Infos |
| NCT02813824 | Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome | Interventional | Phase 3 | Recruitment open | France | Lynch Syndrome | Infos |
| NCT02818907 | Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable | Interventional | Not Applicable | Unknown status | France | Pancreatic Cancer | Infos |
| NCT02820389 | CT Colonography as the Initial Diagnostic Imaging Tool for Patients With Suspected Colorectal Cancer | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02821793 | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02824185 | Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma | Interventional | Not Applicable | Unknown status | France | Patients Eligible to a Curative Treatment for Primary HCC | Infos |
| NCT02824484 | A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSURE | Interventional | Not Applicable | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02841657 | 3D Laparoscopy Versus 2D Laparoscopy | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02842294 | Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer | Observational | N/A | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02842294 | Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer | Observational | N/A | Unknown status | France | Quality of Life | Infos |
| NCT02844608 | Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib | Interventional | Not Applicable | Unknown status | France | Carcinoma, Hepatocellular | Infos |
| NCT02848807 | Chemotherapy-related Toxicity, Nutritional Status and Quality of Life | Interventional | Not Applicable | Unknown status | Poland | Metastatic Colorectal Cancer | Infos |
| NCT02858141 | Onco-geriatric Database of Patients With Pancreatic Cancer | Observational | N/A | Unknown status | France | Pancreatic Neoplasms | Infos |
| NCT02859753 | Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation | Interventional | Not Applicable | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT02861209 | Collaborative Network to Take Responsibility for Oral Anticancer Therapy | Interventional | Not Applicable | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT02861430 | Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT02861430 | Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology | Observational | N/A | Unknown status | France | Lymph Node | Infos |
| NCT02861430 | Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology | Observational | N/A | Unknown status | France | Sentinel Node | Infos |
| NCT02866383 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | Interventional | Phase 2 | Active but recruitment closed | Denmark | Metastatic Biliary Tract Cancer | Infos |
| NCT02866383 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | Interventional | Phase 2 | Active but recruitment closed | Denmark | Metastatic Pancreatic Cancer | Infos |
| NCT02869503 | Institut Paoli Calmettes Colorectal Cancer Database | Observational | N/A | Recruitment open | France | Colorectal Neoplasms | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Greece | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Hungary | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Portugal | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Romania | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Turkey | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Gastric Cancer | Infos |
| NCT02872779 | Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer | Interventional | Not Applicable | Unknown status | France | Circulating Markers | Infos |
| NCT02872779 | Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer | Interventional | Not Applicable | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02873845 | Role of the Spouse/Partner of Persons Treated With Chemotherapy for Colon Cancer | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT02876133 | Narrow Band Imaging Versus White Light for Colonoscopy Serrate Lesions Detection | Interventional | Not Applicable | Unknown status | Portugal | Colon Cancer | Infos |
| NCT02884453 | Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma | Interventional | Phase 2 | Unknown status | United Kingdom | Gastrooesophageal Cancer | Infos |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | Interventional | Phase 3 | Recruitment open | France | Colorectal Neoplasms | Infos |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | Interventional | Phase 3 | Recruitment open | Switzerland | Colorectal Neoplasms | Infos |
| NCT02904031 | Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients | Interventional | Phase 2 | Unknown status | Italy | Elderly Metastatic Colorectal Cancer Patients | Infos |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | Interventional | Phase 3 | Active but recruitment closed | Germany | Colon Adenocarcinoma | Infos |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | Interventional | Phase 3 | Active but recruitment closed | Germany | DNA Repair Disorder | Infos |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | Interventional | Phase 3 | Active but recruitment closed | Germany | Lynch Syndrome | Infos |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | Interventional | Phase 3 | Active but recruitment closed | Germany | Stage III Colon Cancer AJCC v8 | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Austria | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Belgium | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | France | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Germany | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Israel | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Italy | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Netherlands | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Norway | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Portugal | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Spain | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | Sweden | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Interventional | Phase 2 | Recruitment open | United Kingdom | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02919644 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | Interventional | Phase 2 | Recruitment open | Italy | Curative Resection | Infos |
| NCT02919644 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | Interventional | Phase 2 | Recruitment open | Italy | Stage IV Colorectal Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Denmark | Pancreatic Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Finland | Pancreatic Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Norway | Pancreatic Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Sweden | Pancreatic Cancer | Infos |
| NCT02928120 | Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Aberrant DNA Methylation | Infos |
| NCT02928120 | Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Colorectal Neoplasms | Infos |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma | Observational | N/A | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02931890 | Multicentric Randomised Trial for Resectable Gastric Cancer | Interventional | Phase 2 | Recruitment open | Netherlands | Gastric Cancer | Infos |
| NCT02934529 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | Interventional | Phase 3 | Recruitment open | Germany | Metastatic Colorectal Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | Germany | Colon Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | Lithuania | Colon Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | Russian Federation | Colon Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | United Kingdom | Colon Cancer | Infos |
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk | Interventional | Phase 3 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02950324 | Does Prehabilitation Improve Exercise Performance and Insulin Resistance After Surgery for Oesophago-gastric Cancer? | Interventional | Not Applicable | Unknown status | United Kingdom | Cancer | Infos |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Interventional | Phase 2 | Active but recruitment closed | Spain | Colorectal Cancer (CRC) | Infos |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Interventional | Phase 2 | Active but recruitment closed | Spain | Pancreatic Cancer | Infos |
| NCT02956876 | Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer | Interventional | Phase 3 | Unknown status | France | ColoRectal Cancer | Infos |
| NCT02959541 | PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer | Interventional | Not Applicable | Unknown status | Sweden | Chemotherapy | Infos |
| NCT02959541 | PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer | Interventional | Not Applicable | Unknown status | Sweden | Colon Cancer | Infos |
| NCT02967289 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | Interventional | Phase 3 | Active but recruitment closed | France | Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) | Infos |
| NCT02974556 | Proactive Management of Endoperitoneal Spread in Colonic Cancer | Interventional | Phase 3 | Not yet recruiting | Italy | Colon Cancer | Infos |
| NCT02975141 | Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer | Interventional | Phase 1 | Unknown status | Germany | Metastatic Pancreatic Cancer | Infos |
| NCT02978612 | Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III | Interventional | Phase 2 | Active but recruitment closed | Norway | Colon Cancer | Infos |
| NCT02980510 | Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Colorectal Cancer | Infos |
| NCT02992912 | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours | Interventional | Phase 2 | Unknown status | France | Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) | Infos |
| NCT03009227 | Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer | Interventional | Not Applicable | Active but recruitment closed | Russian Federation | Colonic Neoplasms Malignant | Infos |
| NCT03026140 | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | Interventional | Phase 2 | Recruitment open | Netherlands | Colon Carcinoma | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | RET-altered Colon Cancer | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | RET-altered Colon Cancer | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | RET-altered Colon Cancer | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | RET-altered Colon Cancer | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | RET-altered Colon Cancer | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | RET-altered Colon Cancer | Infos |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | RET-altered Colon Cancer | Infos |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer | Interventional | Phase 3 | Recruitment open | France | Gastric Adenocarcinoma | Infos |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Belgium | Metastatic Colorectal Adenocarcinoma | Infos |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Colorectal Adenocarcinoma | Infos |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Italy | Metastatic Colorectal Adenocarcinoma | Infos |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Spain | Metastatic Colorectal Adenocarcinoma | Infos |
| NCT03043950 | Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With VectibixĀ® and FOLFIRI or FOLFOX in First Line (VALIDATE) | Observational | N/A | Active but recruitment closed | Germany | Metastatic Colorectal Cancer | Infos |
| NCT03044223 | Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis | Observational | N/A | Unknown status | Germany | Pseudomonas Gastrointestinal Tract Infection | Infos |
| NCT03044587 | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Non-Resectable Hepatocellular Carcinoma | Infos |
| NCT03045107 | Intracorporeal or Extracorporeal Anastomosis After Laparoscopic Right Colectomy. | Interventional | Not Applicable | Unknown status | Italy | Colon Cancer | Infos |
| NCT03047837 | A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. | Interventional | Phase 2 | Unknown status | Italy | Tertiary Prevention in Colon Cancer | Infos |
| NCT03051152 | D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma | Interventional | Not Applicable | Not yet recruiting | Italy | Gastric Cancer | Infos |
| NCT03052335 | The Efficiency of Colon Capsule Endoscopy in Colon Cancer Screening | Interventional | Not Applicable | Unknown status | Czechia | Colon Cancer | Infos |
| NCT03069508 | Clemizole HCl for Subjects With Hepatocellular Carcinoma | Interventional | Phase 2 | Unknown status | Turkey | Hepatocellular Carcinoma | Infos |
| NCT03069664 | Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic Cancer | Interventional | Not Applicable | Recruitment open | Finland | Pancreatic Cancer | Infos |
| NCT03069664 | Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic Cancer | Interventional | Not Applicable | Recruitment open | Finland | Pancreatic Duct Stricture | Infos |
| NCT03070613 | Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery | Interventional | Early Phase 1 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT03081143 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | Austria | Advanced Gastric or EGJ Cancer | Infos |
| NCT03081143 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | Germany | Advanced Gastric or EGJ Cancer | Infos |
| NCT03081143 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | Italy | Advanced Gastric or EGJ Cancer | Infos |
| NCT03083002 | Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis | Observational | N/A | Unknown status | Italy | Carcinoma, Hepatocellular | Infos |
| NCT03083951 | Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) | Interventional | Not Applicable | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT03083951 | Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) | Interventional | Not Applicable | Unknown status | Spain | Sigmoid Cancer | Infos |
| NCT03088150 | COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation | Interventional | Not Applicable | Recruitment open | Netherlands | ColoRectal Cancer | Infos |
| NCT03088150 | COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation | Interventional | Not Applicable | Recruitment open | Netherlands | Liver Metastasis Colon Cancer | Infos |
| NCT03089268 | Molecular and Histological Characteristics of Serrated Lesions of the Colon | Observational | N/A | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT03096054 | A CR-UK Phase I Trial of LY3143921 | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | a. Colorectal Cancer | Infos |
| NCT03096054 | A CR-UK Phase I Trial of LY3143921 | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | h. Pancreatic Cancer | Infos |
| NCT03097224 | Prehabilitation in Frail Colon Cancer | Interventional | Not Applicable | Unknown status | Belgium | Colon Cancer | Infos |
| NCT03097224 | Prehabilitation in Frail Colon Cancer | Interventional | Not Applicable | Unknown status | Belgium | Fragility | Infos |
| NCT03098758 | Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric Cancer | Observational | N/A | Unknown status | Spain | Gastric Cancer | Infos |
| NCT03098758 | Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric Cancer | Observational | N/A | Unknown status | Spain | Polymerase Chain Reaction | Infos |
| NCT03113318 | Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer | Interventional | Not Applicable | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT03113318 | Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer | Interventional | Not Applicable | Unknown status | Denmark | Lung Neoplasms | Infos |
| NCT03113318 | Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer | Interventional | Not Applicable | Unknown status | Denmark | Neoplasm Metastasis | Infos |
| NCT03117972 | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | Interventional | Phase 2 | Recruitment open | France | Metastatic Colorectal Cancer | Infos |
| NCT03124212 | Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland | Observational | N/A | Recruitment open | Switzerland | Hereditary Breast and Ovarian Cancer | Infos |
| NCT03124212 | Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland | Observational | N/A | Recruitment open | Switzerland | Lynch Syndrome | Infos |
| NCT03126812 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Netherlands | Peritoneal Cancer | Infos |
| NCT03133273 | Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, OncogrammeĀ® (ONCOGRAM) | Interventional | Not Applicable | Active but recruitment closed | France | Chemotherapy | Infos |
| NCT03133273 | Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, OncogrammeĀ® (ONCOGRAM) | Interventional | Not Applicable | Active but recruitment closed | France | Colorectal Cancer Metastatic | Infos |
| NCT03133650 | A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing | Interventional | Phase 1 | Active but recruitment closed | Israel | Esophagogastric Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Austria | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Czechia | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Denmark | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | France | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Italy | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Poland | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Portugal | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Romania | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Spain | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | Turkey | Various Advanced Cancer | Infos |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Various Advanced Cancer | Infos |
| NCT03146338 | Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) | Interventional | Not Applicable | Active but recruitment closed | France | Metastatic Colorectal Cancer | Infos |
| NCT03151252 | Improvement of Foodallergy Diagnostic in Gastrointestinal Tract | Interventional | Not Applicable | Unknown status | Germany | Food Allergy | Infos |
| NCT03153280 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer | Interventional | Phase 1 | Recruitment open | Ireland | Colorectal Neoplasms | Infos |
| NCT03153280 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer | Interventional | Phase 1 | Recruitment open | Ireland | Esophageal Neoplasms | Infos |
| NCT03153280 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer | Interventional | Phase 1 | Recruitment open | Ireland | Stomach Neoplasm | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | Denmark | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | Germany | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | Israel | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | Italy | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | Switzerland | Colon Cancer | Infos |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Colon Cancer | Infos |
| NCT03166436 | RFA for Malignant Biliary Obstruction | Interventional | Not Applicable | Unknown status | Czechia | Pancreas Cancer | Infos |
| NCT03167268 | Panitumumab Skin Toxicity Prevention Trial | Interventional | Phase 2 | Unknown status | Italy | Colorectal Cancer Metastatic | Infos |
| NCT03167814 | Prevention of Chyle-leak After Major Pancreatic Surgery | Interventional | Not Applicable | Recruitment open | Finland | Pancreatic Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Lower Esophageal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Lower Esophageal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Lower Esophageal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Lower Esophageal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Lower Esophageal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Lower Esophageal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Gastric Cancer | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Lower Esophageal Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Finland | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | France | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Hungary | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Russian Federation | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Ukraine | Gastric Cancer | Infos |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Gastric Cancer | Infos |
| NCT03178812 | Role of the Cystic Fluid Interleukins and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS) | Interventional | Not Applicable | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT03186326 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Colorectal Cancer | Infos |
| NCT03189576 | Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases | Interventional | Not Applicable | Active but recruitment closed | Finland | Colorectal Cancer | Infos |
| NCT03189576 | Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases | Interventional | Not Applicable | Active but recruitment closed | Finland | Residual Disease | Infos |
| NCT03191110 | The COLON Study: Colorectal Cancer Cohort | Observational | N/A | Recruitment open | Netherlands | Colorectal Neoplasms Malignant | Infos |
| NCT03193190 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | Germany | Pancreatic Adenocarcinoma | Infos |
| NCT03193190 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Pancreatic Adenocarcinoma | Infos |
| NCT03200834 | Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON) | Interventional | Not Applicable | Active but recruitment closed | Ukraine | Colon Cancer | Infos |
| NCT03205735 | The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line | Observational | N/A | Unknown status | France | Metastatic or Locally-advanced Digestive Cancer | Infos |
| NCT03208621 | Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer | Observational | N/A | Active but recruitment closed | Netherlands | Diagnostic Laparoscopy | Infos |
| NCT03208621 | Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer | Observational | N/A | Active but recruitment closed | Netherlands | FDG-PET/CT | Infos |
| NCT03208621 | Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer | Observational | N/A | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT03208621 | Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer | Observational | N/A | Active but recruitment closed | Netherlands | Staging | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Austria | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Austria | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Austria | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Belgium | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Belgium | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Belgium | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Denmark | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Denmark | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Denmark | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | France | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | France | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | France | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Germany | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Germany | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Germany | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Italy | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Italy | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Poland | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Poland | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Poland | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Russian Federation | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Russian Federation | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Russian Federation | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Russian Federation | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Spain | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Spain | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Spain | Pancreas Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Switzerland | Appendix Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Switzerland | Gastric Cancer | Infos |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | Observational | N/A | Unknown status | Switzerland | Pancreas Cancer | Infos |
| NCT03210948 | Conventional Versus Elastography Targeted Endoscopic Ultrasound Fine Needle Aspiration of Solid Pancreatic Lesions | Interventional | Not Applicable | Unknown status | Italy | Pancreas Cancer | Infos |
| NCT03212469 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Oesophageal Cancer | Infos |
| NCT03214939 | Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer | Interventional | Early Phase 1 | Unknown status | Russian Federation | Colorectal Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Estonia | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | France | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Germany | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Israel | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Latvia | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Lithuania | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Poland | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Gastric Cancer | Infos |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Gastric Cancer | Infos |
| NCT03225937 | Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT03232541 | The Effects of Acupuncture and the TherapistĀ“s Communication on Chemotherapy Induced Nausea and Vomiting | Interventional | Not Applicable | Recruitment open | Sweden | Colorectal Cancer | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Appetite Loss | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Cachexia; Cancer | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Cannabis | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Morbidity | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Mortality | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Neoplasms Pancreatic | Infos |
| NCT03245658 | The Effect of Cannabis in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Denmark | Palliative Medicine | Infos |
| NCT03246516 | Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers | Interventional | Not Applicable | Active but recruitment closed | France | Gastric Adenocarcinoma | Infos |
| NCT03246516 | Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers | Interventional | Not Applicable | Active but recruitment closed | France | Oesophageal Carcinoma | Infos |
| NCT03250091 | Surveillance of Patients With Precancerous Lesions of the Stomach | Observational | N/A | Recruitment open | Latvia | Gastric Cancer | Infos |
| NCT03251365 | Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | Interventional | Phase 2/Phase 3 | Recruitment open | Spain | Resectable Pancreatic Adenocarcinoma | Infos |
| NCT03253536 | Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma | Observational | N/A | Recruitment open | Germany | Hepatocellular Cancer | Infos |
| NCT03253536 | Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma | Observational | N/A | Recruitment open | Germany | Observational | Infos |
| NCT03253536 | Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma | Observational | N/A | Recruitment open | Germany | Quality of Life | Infos |
| NCT03253536 | Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma | Observational | N/A | Recruitment open | Germany | Stereotactic Body Radiation Therapy | Infos |
| NCT03254836 | Sleep and Survival in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Circadian Rhythm Sleep Disorder | Infos |
| NCT03254836 | Sleep and Survival in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Colorectal Neoplasm | Infos |
| NCT03254836 | Sleep and Survival in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Depression | Infos |
| NCT03254836 | Sleep and Survival in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Quality of Life | Infos |
| NCT03254836 | Sleep and Survival in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Sleep | Infos |
| NCT03255434 | LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy | Interventional | Phase 2 | Active but recruitment closed | France | Stage III Colon Cancer | Infos |
| NCT03256084 | Tumoral Circulating Cells and Colorectal Cancer Progression | Interventional | Not Applicable | Recruitment open | France | Colorectal Cancer | Infos |
| NCT03257033 | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Interventional | Phase 3 | Recruitment open | Belgium | Locally Advanced Pancreatic Cancer | Infos |
| NCT03257280 | Trial on Impact on the Hospital Stay, of an Early Oral Nutrition Protocol Applied to Patients After Total Gastrectomy. (DOPGT_2015) | Interventional | Not Applicable | Unknown status | Spain | Gastric Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Estonia | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Latvia | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Lithuania | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Interventional | Phase 1/Phase 2 | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT03277144 | Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer. A Randomized Controlled Trial | Interventional | Not Applicable | Unknown status | Italy | Duodenal Stump Leak | Infos |
| NCT03277144 | Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer. A Randomized Controlled Trial | Interventional | Not Applicable | Unknown status | Italy | Gastric Cancer | Infos |
| NCT03280407 | NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer | Interventional | Phase 2 | Recruitment open | Denmark | Colorectal Cancer | Infos |
| NCT03280511 | Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Colo-rectal Cancer | Infos |
| NCT03280511 | Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Peritoneal Carcinomatosis | Infos |
| NCT03280511 | Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Peritoneal Metastases | Infos |
| NCT03280511 | Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Peritoneum Cancer | Infos |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | France | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Infos |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | Germany | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Infos |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | Israel | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Infos |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | Netherlands | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Infos |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Infos |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Infos |
| NCT03283527 | Organoid Based Response Prediction in Esophageal Cancer | Observational | N/A | Recruitment open | Netherlands | Chemoradiation | Infos |
| NCT03283527 | Organoid Based Response Prediction in Esophageal Cancer | Observational | N/A | Recruitment open | Netherlands | Esophageal Cancer | Infos |
| NCT03283527 | Organoid Based Response Prediction in Esophageal Cancer | Observational | N/A | Recruitment open | Netherlands | Organoid | Infos |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Interventional | Phase 1 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Interventional | Phase 1 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Interventional | Phase 1 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Interventional | Phase 1 | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma | Infos |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Hepatocellular Carcinoma | Infos |
| NCT03301454 | Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer | Interventional | Phase 2 | Unknown status | France | Esophageal Cancer, Squamous Cell | Infos |
| NCT03303833 | The GEOLynch Cohort Study | Observational | N/A | Recruitment open | Netherlands | Hereditary Nonpolyposis Colorectal Cancer | Infos |
| NCT03303833 | The GEOLynch Cohort Study | Observational | N/A | Recruitment open | Netherlands | Lynch Syndrome | Infos |
| NCT03307408 | Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease | Observational | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT03309722 | Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer Progression | Observational | N/A | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT03310008 | Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | Interventional | Phase 1 | Unknown status | Belgium | Colon Cancer Liver Metastasis | Infos |
| NCT03311152 | Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis | Interventional | Not Applicable | Recruitment open | France | Cirrhosis | Infos |
| NCT03311152 | Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis | Interventional | Not Applicable | Recruitment open | France | Hepatocellular Carcinoma | Infos |
| NCT03311776 | BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC") | Observational | N/A | Recruitment open | Denmark | Pancreatic Cancer | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Denmark | Colorectal Cancer | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Denmark | Colorectal Cancer Liver Metastases | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Denmark | Liver Metastases | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Norway | Colorectal Cancer Liver Metastases | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Norway | Liver Metastases | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Sweden | Colorectal Cancer Liver Metastases | Infos |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Sweden | Liver Metastases | Infos |
| NCT03334708 | A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma | Observational | N/A | Recruitment open | Israel | Pancreatic Cancer | Infos |
| NCT03336229 | Enhancing Fitness With Preoperative Exercise in Colorectal Cancer Surgery | Interventional | Not Applicable | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT03340259 | Intestinal Colonization in Newborn Infants With Enterostomy | Observational | N/A | Unknown status | Portugal | Newborn Infants With Enterostomy by Congenital Malformations of the Gastrointestinal Tract, Necrotizing Enterocolitis and Spontaneous Intestinal Perforation | Infos |
| NCT03340636 | Residual Plasma Concentration of Sorafenib and Adverse Events in CHC | Observational | N/A | Unknown status | France | Advanced or Metastatic Hepatocellular Carcinoma | Infos |
| NCT03348150 | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. | Interventional | Phase 3 | Recruitment open | Netherlands | Peritoneal Carcinomatosis | Infos |
| NCT03348150 | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. | Interventional | Phase 3 | Recruitment open | Netherlands | Stomach Neoplasm | Infos |
| NCT03350126 | Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Cancer Colorectal | Infos |
| NCT03350412 | Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials | Observational | N/A | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT03351296 | Two Chemotherapy Regimens Plus or Minus Bevacizumab | Interventional | Phase 2 | Recruitment open | France | Pancreatic Cancer | Infos |
| NCT03357991 | E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM | Observational | N/A | Unknown status | Spain | Anal Cancer | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Austria | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Bulgaria | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | France | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Germany | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Greece | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Hungary | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Italy | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Poland | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Portugal | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Romania | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Russian Federation | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Spain | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Turkey | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Ukraine | Chemotherapy-induced Thrombocytopenia | Infos |
| NCT03370198 | Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer | Interventional | Phase 1 | Unknown status | Belgium | Colon Cancer Liver Metastasis | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Czechia | Colorectal Cancer | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Russian Federation | Colorectal Cancer | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT03380858 | REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT03383367 | Colorectal Cancer Screening French Organizations for the Follow-up After Colonoscopy | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Austria | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Austria | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Belgium | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | France | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Germany | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Italy | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Poland | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Romania | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Romania | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | Spain | Liver Cancer | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Liver Cancer | Infos |
| NCT03388190 | METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin | Interventional | Phase 2 | Active but recruitment closed | Norway | Colorectal Cancer Metastatic | Infos |
| NCT03390764 | Hernia After Colorectal Cancer Surgery | Interventional | Not Applicable | Active but recruitment closed | Sweden | Incisional Hernia | Infos |
| NCT03390764 | Hernia After Colorectal Cancer Surgery | Interventional | Not Applicable | Active but recruitment closed | Sweden | Quality of Life | Infos |
| NCT03390764 | Hernia After Colorectal Cancer Surgery | Interventional | Not Applicable | Active but recruitment closed | Sweden | Wound Complication | Infos |
| NCT03390764 | Hernia After Colorectal Cancer Surgery | Interventional | Not Applicable | Active but recruitment closed | Sweden | Wound Dehiscence | Infos |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Gastric Adenocarcinoma | Infos |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Oesophageal Adenocarcinoma | Infos |
| NCT03400072 | Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial | Interventional | Not Applicable | Recruitment open | France | Pancreas Cancer | Infos |
| NCT03400072 | Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial | Interventional | Not Applicable | Recruitment open | France | Quality of Life | Infos |
| NCT03400280 | POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection | Interventional | Not Applicable | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT03408665 | Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | Interventional | Not Applicable | Recruitment open | France | Liver Cancer | Infos |
| NCT03408665 | Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | Interventional | Not Applicable | Recruitment open | France | Liver Metastases | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | Czechia | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | Slovakia | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03412773 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma (HCC) | Infos |
| NCT03413254 | Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases | Interventional | Phase 3 | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT03413254 | Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases | Interventional | Phase 3 | Recruitment open | Netherlands | Peritoneal Metastases | Infos |
| NCT03418558 | Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib. | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | Interventional | Phase 2 | Recruitment open | Germany | Gastric Cancer | Infos |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | Interventional | Phase 2 | Recruitment open | Switzerland | Gastric Cancer | Infos |
| NCT03422601 | Prognostic Value of the ImmunoscoreĀ® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT03422601 | Prognostic Value of the ImmunoscoreĀ® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment | Observational | N/A | Unknown status | France | Stage III Colon Cancer | Infos |
| NCT03428477 | EPA for Metastasis Trial 2 | Interventional | Phase 3 | Recruitment open | United Kingdom | Colon Cancer | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colorectal Carcinoma | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colorectal Neoplasms | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colorectal Tumors | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | France | Neoplasms, Colorectal | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Colorectal Carcinoma | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Colorectal Neoplasms | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Colorectal Tumors | Infos |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Neoplasms, Colorectal | Infos |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Cancer | Infos |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Peritoneal Cancer | Infos |
| NCT03434925 | Multi Parametric Test Predicting the Risk of Colorectal Neoplasia Recurrence | Interventional | Not Applicable | Unknown status | Czechia | Colon Cancer | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Czechia | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | France | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Germany | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Israel | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Italy | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Norway | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Poland | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Portugal | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | Spain | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Gastric and Esophagogastric Junction Adenocarcinoma | Infos |
| NCT03444194 | Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study | Interventional | Not Applicable | Unknown status | Denmark | Liver Metastasis Colon Cancer | Infos |
| NCT03445936 | PRELOOP Trial: Synthetic Versus Biological Mesh for Prevention of Incisional Hernia After Loop-ileostomy Closure | Interventional | Not Applicable | Active but recruitment closed | Finland | Rectum Cancer | Infos |
| NCT03447431 | Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT03447431 | Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact | Observational | N/A | Unknown status | France | Microsatellite Instability | Infos |
| NCT03449264 | Development of Clinical and Biological Database | Interventional | Not Applicable | Recruitment open | France | Digestive Cancer | Infos |
| NCT03449914 | The GOLD Study: G8 in OLDer Patients | Observational | N/A | Active but recruitment closed | Italy | Elderly Metastatic Colorectal Cancer Patients | Infos |
| NCT03451370 | First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer | Observational | N/A | Active but recruitment closed | Italy | Elderly Metastatic Colorectal Cancer Patients | Infos |
| NCT03451643 | Stenting and Resection for Stage IV Colorectal Cancer Endoscopic Stenting and Colorectal Resection in Stage IV | Interventional | Not Applicable | Unknown status | Italy | Colorectal Neoplasm | Infos |
| NCT03452319 | Effects of Increased Physical Activity Before Thoracoabdominal Esophageal Surgery | Interventional | Not Applicable | Recruitment open | Sweden | Oesophageal Cancer | Infos |
| NCT03458949 | Pilot Study in a Company in Maine-et-Loire to Evaluate the Feasibility, Acceptability, and Impact on the Participation Rate of Awareness of Colorectal Cancer Screening by Occupational Health Teams | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT03460925 | Improving REsectability in Pancreatic NEoplasms (IRENE) | Interventional | Not Applicable | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT03462992 | Peripheral Blood Monocytes as Predictive Marker for Colorectal Cancer Diagnosis: A Comparative Study of a Stool Based Versus Blood Based Screening Test | Observational | N/A | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT03464305 | ASPIRIN Trial Belgium | Interventional | Phase 3 | Recruitment open | Belgium | Colon Cancer | Infos |
| NCT03468335 | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy | Interventional | Phase 3 | Active but recruitment closed | Germany | Locally Advanced Pancreatic Cancer | Infos |
| NCT03468335 | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy | Interventional | Phase 3 | Active but recruitment closed | Germany | Metastatic Pancreatic Cancer | Infos |
| NCT03469726 | Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Greece | Pancreatic Neoplasms | Infos |
| NCT03469726 | Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Netherlands | Pancreatic Neoplasms | Infos |
| NCT03469726 | Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Spain | Pancreatic Neoplasms | Infos |
| NCT03469726 | Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer | Interventional | Not Applicable | Unknown status | Switzerland | Pancreatic Neoplasms | Infos |
| NCT03474341 | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | Observational | N/A | Unknown status | Netherlands | Esophageal Adenocarcinoma | Infos |
| NCT03474341 | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | Observational | N/A | Unknown status | Netherlands | Esophageal Cancer | Infos |
| NCT03474341 | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | Observational | N/A | Unknown status | Netherlands | Esophageal Neoplasms | Infos |
| NCT03474341 | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | Observational | N/A | Unknown status | Netherlands | Esophageal Squamous Cell Carcinoma | Infos |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colorectal Cancer Not MSI-H or MMR-deficient | Infos |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | France | Hepatocellular Carcinoma | Infos |
| NCT03482362 | Vinorelbine in Advanced BRAF-like Colon Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Colon Cancer | Infos |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Interventional | Phase 2 | Recruitment open | France | Exocrine Pancreatic Cancer | Infos |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Interventional | Phase 2 | Recruitment open | Germany | Exocrine Pancreatic Cancer | Infos |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Interventional | Phase 2 | Recruitment open | Italy | Exocrine Pancreatic Cancer | Infos |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Interventional | Phase 2 | Recruitment open | Spain | Exocrine Pancreatic Cancer | Infos |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Interventional | Phase 2 | Recruitment open | United Kingdom | Exocrine Pancreatic Cancer | Infos |
| NCT03486730 | BT1718 in Patients With Advanced Solid Tumours. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Oesophageal Cancer | Infos |
| NCT03487016 | First-line Therapy in Metastatic PDAC | Interventional | Phase 2 | Active but recruitment closed | Germany | Metastatic Pancreatic Cancer | Infos |
| NCT03488953 | Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases | Interventional | Not Applicable | Recruitment open | Germany | Colorectal Cancer Metastatic | Infos |
| NCT03490565 | PREoperativ Study of Exercise Training | Interventional | Not Applicable | Active but recruitment closed | Denmark | GastroEsophageal Cancer | Infos |
| NCT03494946 | Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer | Interventional | Not Applicable | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT03494946 | Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer | Interventional | Not Applicable | Recruitment open | Norway | Liver Metastases | Infos |
| NCT03500068 | Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. | Interventional | Not Applicable | Unknown status | Netherlands | Carcinoma, Pancreatic Ductal | Infos |
| NCT03505320 | A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Interventional | Phase 2 | Recruitment open | France | Gastric Cancer | Infos |
| NCT03505320 | A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Interventional | Phase 2 | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT03507140 | Microbiota Study in Liver Transplanted Patients | Observational | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT03510858 | Randomized Controlled Trial on Colorectal Cancer Screening Among Quality Circles of Primary Care Physicians | Interventional | Not Applicable | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | Observational | N/A | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | Observational | N/A | Unknown status | Switzerland | Gastric Cancer | Infos |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | Observational | N/A | Unknown status | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT03519178 | A Study of PF-06873600 in People With Cancer | Interventional | Phase 2 | Active but recruitment closed | Bulgaria | HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Infos |
| NCT03519178 | A Study of PF-06873600 in People With Cancer | Interventional | Phase 2 | Active but recruitment closed | Russian Federation | HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Infos |
| NCT03519178 | A Study of PF-06873600 in People With Cancer | Interventional | Phase 2 | Active but recruitment closed | Ukraine | HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Infos |
| NCT03519295 | A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma | Interventional | Phase 2 | Unknown status | France | Anal Cancer | Infos |
| NCT03519412 | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status | Interventional | Phase 2 | Recruitment open | Italy | Colorectal Neoplasms | Infos |
| NCT03519412 | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status | Interventional | Phase 2 | Recruitment open | Italy | Microsatellite Instability | Infos |
| NCT03520946 | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT03524677 | Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis | Observational | N/A | Unknown status | Ireland | Pancreatic Cancer | Infos |
| NCT03524677 | Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis | Observational | N/A | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Belgium | Gastric Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | France | Gastric Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Colorectal Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Gastric Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Gastric Cancer | Infos |
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Italy | Pancreatic Adenocarcinoma | Infos |
| NCT03530267 | Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT03536793 | Tumour Regulatory Molecules in Early Pancreatic Cancer Detection | Observational | N/A | Recruitment open | United Kingdom | Cancer of Pancreas | Infos |
| NCT03536793 | Tumour Regulatory Molecules in Early Pancreatic Cancer Detection | Observational | N/A | Recruitment open | United Kingdom | Pancreas Cyst | Infos |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Esophageal Cancer | Infos |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Esophageal Cancer | Infos |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Norway | Esophageal Cancer | Infos |
| NCT03551470 | Minimally Invasive Simultaneous Colorectal and Liver Surgery | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT03562234 | The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT03562234 | The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases | Observational | N/A | Unknown status | United Kingdom | Liver Metastasis Colon Cancer | Infos |
| NCT03563586 | Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery | Interventional | Not Applicable | Unknown status | Greece | Antibiotic | Infos |
| NCT03563586 | Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery | Interventional | Not Applicable | Unknown status | Greece | Bowel Cancer | Infos |
| NCT03563586 | Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery | Interventional | Not Applicable | Unknown status | Greece | Colorectal Cancer | Infos |
| NCT03563586 | Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery | Interventional | Not Applicable | Unknown status | Greece | Surgical Site Infection | Infos |
| NCT03564340 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Belgium | Recurrent Primary Peritoneal Cancer | Infos |
| NCT03564340 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | France | Recurrent Primary Peritoneal Cancer | Infos |
| NCT03564340 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Recurrent Primary Peritoneal Cancer | Infos |
| NCT03564340 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Recurrent Primary Peritoneal Cancer | Infos |
| NCT03568110 | Frailty and Postoperative Outcomes After Gastric Cancer Surgery | Observational | N/A | Recruitment open | Spain | Frail Elderly Syndrome | Infos |
| NCT03568110 | Frailty and Postoperative Outcomes After Gastric Cancer Surgery | Observational | N/A | Recruitment open | Spain | Gastric Cancer | Infos |
| NCT03568110 | Frailty and Postoperative Outcomes After Gastric Cancer Surgery | Observational | N/A | Recruitment open | Spain | Postoperative Complications | Infos |
| NCT03568110 | Frailty and Postoperative Outcomes After Gastric Cancer Surgery | Observational | N/A | Recruitment open | Spain | Quality of Life | Infos |
| NCT03570502 | Incidence of POPF in the Resection of the Left Pancreas With RFAT | Observational | N/A | Unknown status | Spain | Pancreas Cancer | Infos |
| NCT03579004 | Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer | Interventional | Phase 2 | Unknown status | Russian Federation | Concurrent Chemoradiotherapy | Infos |
| NCT03579004 | Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer | Interventional | Phase 2 | Unknown status | Russian Federation | Esophageal Neoplasms | Infos |
| NCT03579004 | Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer | Interventional | Phase 2 | Unknown status | Russian Federation | Squamous Cell Carcinoma | Infos |
| NCT03584711 | FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Colorectal Cancer | Infos |
| NCT03587532 | Assessment of Graft Perfusion and Oxygenation for Improved Outcome in Esophageal Cancer Surgery | Interventional | Not Applicable | Recruitment open | Belgium | Anastomotic Leak | Infos |
| NCT03587532 | Assessment of Graft Perfusion and Oxygenation for Improved Outcome in Esophageal Cancer Surgery | Interventional | Not Applicable | Recruitment open | Belgium | Esophageal Cancer | Infos |
| NCT03588416 | Multicentric Study About Pathological Risk Factors for Lymph Node Metastasis in Malignant Colorectal Polyps | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT03602677 | Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage | Interventional | Not Applicable | Recruitment open | Finland | Colorectal Cancer | Infos |
| NCT03602677 | Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage | Interventional | Not Applicable | Recruitment open | Finland | Gastrointestinal Cancer | Infos |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Interventional | Phase 2 | Unknown status | Czechia | Hepatocellular Carcinoma | Infos |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Interventional | Phase 2 | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Interventional | Phase 2 | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Interventional | Phase 2 | Unknown status | Italy | Hepatocellular Carcinoma | Infos |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Interventional | Phase 2 | Unknown status | Poland | Hepatocellular Carcinoma | Infos |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Interventional | Phase 2 | Unknown status | Spain | Hepatocellular Carcinoma | Infos |
| NCT03606863 | Peripheral Parenteral Nutrition vs Conventional Fluid in Colorectal Resection in ERAS | Interventional | Phase 3 | Unknown status | Spain | Colon Cancer | Infos |
| NCT03612674 | Adenoma Detection Rate With Endocuff-Assisted Colonoscopy - an Italian Trial | Interventional | Not Applicable | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT03613194 | Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours | Interventional | Phase 2 | Recruitment open | United Kingdom | Gastric Cancer | Infos |
| NCT03620877 | A Program for Improved Family Screening for Colorectal Cancer | Interventional | Not Applicable | Unknown status | France | Colorectal Cancer | Infos |
| NCT03620916 | Comparison of Intrathecal and Intravenous Analgesia in Patients Undergoing Liver Resection | Interventional | Not Applicable | Unknown status | Poland | Liver Cancer | Infos |
| NCT03621644 | Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer | Interventional | Not Applicable | Active but recruitment closed | Israel | Pancreatic Cancer | Infos |
| NCT03621852 | Prospective Evaluation of the Diagnostic Efficacy of a EUS Guided FNB Needle (AQUIREĀ®) | Observational | N/A | Unknown status | Germany | Submucosal Tumor of Gastrointestinal Tract (Disorder) | Infos |
| NCT03627728 | Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer | Interventional | Phase 2 | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation | Interventional | Phase 2 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT03631173 | Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy | Interventional | Not Applicable | Active but recruitment closed | Norway | Pancreatic Cancer | Infos |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT03637686 | Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer | Observational | N/A | Active but recruitment closed | Denmark | Colorectal Cancer | Infos |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Adenocarcinoma of the Stomach | Infos |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | GastroEsophageal Cancer | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Fallopian Tube Cancer | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Fallopian Tube Neoplasms | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Ovarian Cancer | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Ovarian Carcinosarcoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Ovarian Clear Cell Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Ovarian Endometrioid Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Ovarian Neoplasms | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Ovarian Serous Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Primary Peritoneal Carcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | Germany | Primary Peritoneal Serous Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Fallopian Tube Neoplasms | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Cancer | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Carcinosarcoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Clear Cell Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Endometrioid Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Neoplasms | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Serous Adenocarcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Primary Peritoneal Carcinoma | Infos |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Primary Peritoneal Serous Adenocarcinoma | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Croatia | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Finland | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Greece | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Portugal | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT03650517 | Minimally Invasive Right Colectomy Anastomosis Study | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT03653052 | Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Oesophageal Cancer | Infos |
| NCT03654131 | Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver | Interventional | Phase 2 | Recruitment open | Denmark | Colorectal Carcinoma | Infos |
| NCT03654131 | Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver | Interventional | Phase 2 | Recruitment open | Denmark | Liver Metastases | Infos |
| NCT03658837 | Gastrointestinal Functional Outcome Ivor Lewis | Observational | N/A | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT03659448 | Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Germany | Colorectal Neoplasms | Infos |
| NCT03659448 | Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Italy | Colorectal Neoplasms | Infos |
| NCT03659448 | Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Netherlands | Colorectal Neoplasms | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Austria | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Belgium | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Czechia | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | France | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Germany | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Norway | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Poland | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Gastric Cancer | Infos |
| NCT03667612 | Endogenous Mechanisms of Inactivation of the Endothelium Tumor | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT03668418 | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | Observational | N/A | Unknown status | Italy | Esophageal Cancer | Infos |
| NCT03668418 | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT03668418 | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | Observational | N/A | Unknown status | Italy | Liver Cancer | Infos |
| NCT03668418 | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | Observational | N/A | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT03670199 | Improving the Quality of Life of Cancer Patients Through a Perioperative and Coordinated Nutrition and Physical Care Program. | Interventional | Not Applicable | Recruitment open | France | Digestive Cancer | Infos |
| NCT03673423 | Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer | Observational | N/A | Unknown status | Italy | Pancreatic Adenocarcinoma | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Belgium | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Czechia | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | France | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Germany | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Hungary | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Israel | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Italy | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Netherlands | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Norway | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Poland | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Spain | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Sweden | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | Switzerland | Gastrointestinal Stromal Tumors | Infos |
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Interventional | Phase 3 | Unknown status | United Kingdom | Gastrointestinal Stromal Tumors | Infos |
| NCT03674801 | Status of Superficial Esophageal Cancers Treated by Endoscopy "OESOFARE" | Observational | N/A | Active but recruitment closed | France | Superficial Esophageal Cancers | Infos |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival | Interventional | Not Applicable | Unknown status | Belgium | Esophageal Cancer | Infos |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival | Interventional | Not Applicable | Unknown status | Belgium | Jejunostomy; Complications | Infos |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival | Interventional | Not Applicable | Unknown status | Belgium | Muscle Weakness | Infos |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival | Interventional | Not Applicable | Unknown status | Belgium | Nutrition Aspect of Cancer | Infos |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival | Interventional | Not Applicable | Unknown status | Belgium | Postoperative Complications | Infos |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival | Interventional | Not Applicable | Unknown status | Belgium | Sarcopenia | Infos |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Interventional | Phase 2 | Recruitment open | France | Pancreas Cancer | Infos |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Interventional | Phase 2 | Recruitment open | France | Pancreatic Cancer | Infos |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Interventional | Phase 2 | Recruitment open | Netherlands | Pancreas Cancer | Infos |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Interventional | Phase 2 | Recruitment open | Netherlands | Pancreatic Cancer | Infos |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Interventional | Phase 2 | Recruitment open | Spain | Pancreas Cancer | Infos |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Interventional | Phase 2 | Recruitment open | Spain | Pancreatic Cancer | Infos |
| NCT03679169 | Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy | Interventional | Not Applicable | Recruitment open | France | Pancreatic Cancer | Infos |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT03685370 | PERiX: Comparison of Efficacy Between Placement of Epidural Catheters X-ray Guided and LOS Technique | Interventional | Not Applicable | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT03690323 | Pancreatic Locally Advanced Irresectable Cancer Ablation | Interventional | Not Applicable | Unknown status | Netherlands | Locally Advanced Pancreatic Cancer | Infos |
| NCT03692429 | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Interventional | Phase 1 | Recruitment open | Belgium | Unresectable Metastatic Colorectal Cancer | Infos |
| NCT03692429 | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Interventional | Phase 1 | Recruitment open | United Kingdom | Unresectable Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Austria | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Belgium | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | France | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Italy | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Netherlands | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Spain | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693170 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT03693677 | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI | Interventional | Phase 2 | Recruitment open | France | Metastatic Pancreatic Cancer | Infos |
| NCT03694080 | Calcium Electroporation for Early Colorectal Cancer | Interventional | Phase 1 | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT03694938 | Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients | Interventional | Not Applicable | Recruitment open | France | Metastatic Colon Cancer | Infos |
| NCT03697044 | Irinotecan Drug-eluting Bead Liver Embolisation Registry | Observational | N/A | Not yet recruiting | United Kingdom | Colorectal Cancer Metastatic | Infos |
| NCT03699163 | The Colorectal Breath Analysis (COBRA) Study | Observational | N/A | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT03699332 | Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT03699332 | Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Gastrointestinal Cancer | Infos |
| NCT03700411 | Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery | Interventional | Phase 4 | Recruitment open | Czechia | Circulating Tumor Cell | Infos |
| NCT03700411 | Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery | Interventional | Phase 4 | Recruitment open | Czechia | Colorectal Cancer | Infos |
| NCT03700541 | Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery | Interventional | Phase 4 | Recruitment open | Czechia | Circulating Tumor Cell | Infos |
| NCT03700541 | Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery | Interventional | Phase 4 | Recruitment open | Czechia | Colorectal Cancer | Infos |
| NCT03705442 | Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Croatia | Colorectal Cancer Metastatic | Infos</ |